Related Experiment Video
Updated: Jun 12, 2025
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?
Stephen J Nicholls1, Sean Tan1, Julie Butters1
1Victorian Heart Institute, Monash University, Melbourne, Australia.
Introduction:
Cholesteryl ester transfer protein (CETP) plays an important role in lipid metabolism. Early interest in the development of CETP inhibitors proved to be disappointing. Recent interest has focused on the potential for CETP inhibition to reduce cardiovascular risk by lowering levels of low-density lipoprotein cholesterol (LDL-C).
Areas Covered:
The data suggesting that low CETP activity may associate with lower levels of cardiovascular risk and early experience with CETP inhibitors focused on raising HDL-C levels. More recent data that suggests that any potential to reduce cardiovascular risk by inhibition of CETP is more likely to result from lowering levels of atherogenic lipid parameters. The development of obicetrapib, a potent CETP inhibitor, with robust lowering of apoB and LDL-C, will be summarized as a potential approach to the prevention of cardiovascular disease.
Expert Opinion:
Obicetrapib is a potent CETP inhibitor, with a demonstrated ability to lower levels of apoB and LDL-C as monotherapy and in addition to high intensity statin therapy. The ultimate impact of obicetrapib on cardiovascular events will be evaluated by ongoing clinical trials.
Insights
Cholesteryl ester transfer protein (CETP) inhibitors, like obicetrapib, show promise in reducing cardiovascular risk by lowering LDL-C. Ongoing trials will determine their ultimate impact on cardiovascular events.
Area of Science:
- Lipid metabolism and cardiovascular disease research.
Background:
- Cholesteryl ester transfer protein (CETP) is crucial in lipid metabolism.
- Early CETP inhibitors disappointed, but recent focus is on reducing cardiovascular risk.
- Newer CETP inhibitors aim to lower atherogenic lipids, not just HDL-C.
Purpose of the Study:
- To summarize the development of obicetrapib, a potent CETP inhibitor.
- To highlight obicetrapib's potential in cardiovascular disease prevention.
Main Methods:
- Review of data on CETP inhibition and lipid parameters.
- Focus on obicetrapib's efficacy in lowering apoB and LDL-C.
Main Results:
- Obicetrapib effectively lowers apoB and LDL-C as monotherapy.
- Obicetrapib demonstrates efficacy when added to high-intensity statin therapy.
Conclusions:
- Obicetrapib represents a potential strategy for cardiovascular disease prevention.
- Ongoing clinical trials are evaluating obicetrapib's effect on cardiovascular events.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:21Drugs for Treatment of Constipation-Predominant IBS
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...